Hypervision Surgical, a medical technology company developing real-time hyperspectral imaging systems for surgery, has secured £17 million in Series A funding.
The round included Angelini Ventures, HERAN Partners, Redalpine, LifeX Ventures, ZEISS Ventures, and SINC Fund, managed by SAGES Ingenuity. The capital will support commercial expansion and accelerate product research and development as the company advances its surgical intelligence platform.
What The Company Does
Hypervision Surgical builds imaging technology designed to give surgeons deeper visibility into tissue during operations. Its platform combines proprietary hyperspectral sensing with AI-driven analytics to generate real-time, quantitative data in the operating theatre.
Unlike conventional imaging systems that primarily show anatomical structure, hyperspectral imaging captures additional spectral information from tissue. This can help identify characteristics that may not be visible to the naked eye or standard cameras.
The company is developing its platform for integration across multiple surgical environments, including laparoscopic, robotic, microscopic, and endoscopic systems. The goal is to provide clinicians with better intraoperative information that supports faster and more precise decision-making.
Advertisement
Market Context / Industry Background
Demand for smarter surgical technologies has increased as hospitals seek to improve outcomes, reduce complications, and optimise operating room efficiency. Imaging, robotics, navigation software, and AI-assisted decision tools have become key areas of investment within medtech.
Minimally invasive and robotic procedures in particular require advanced visualisation systems, since surgeons often rely on screens and instrument feedback rather than direct sight. Technologies that improve tissue recognition, blood flow assessment, and margin detection are attracting growing commercial and clinical interest.
Europe remains a strong centre for surgical innovation, supported by university research institutions, specialist medtech investors, and strategic corporate venture arms from established healthcare groups.
Adoption of these technologies is also being influenced by rising healthcare costs and pressure on hospital systems to increase surgical throughput without expanding infrastructure. Machine learning models are increasingly integrated into imaging platforms to support real-time decision-making during complex procedures. Regulatory approval processes remain a key factor shaping the pace of commercialisation, particularly in Europe where medical device standards are highly stringent. Training requirements for surgeons are also evolving, with simulation-based systems and digital twins enabling more precise preparation before real-world operations.
Long-term, integration between surgical robotics, imaging systems, and hospital data infrastructure is expected to define the next phase of operating room innovation. Investment activity is expected to continue accelerating as both established medtech companies and early-stage startups compete to develop platforms that combine surgical precision with real-time data intelligence and improved patient safety outcomes across global healthcare systems over the coming decade and beyond globally at scale.
Founder / Investor Commentary
Chief executive and co-founder Michael Ebner described the Series A as an important step in the company’s development. He said the business aims to power surgical intelligence through hyperspectral vision by combining advanced sensing with cloud-enabled AI analytics.
Ebner added that the company is building a new intelligence layer for surgery, giving clinicians access to real-time tissue insights that were previously difficult or impossible to obtain during procedures.
Growth Plans / Use Of Funds
The newly raised funding will be used to expand operations and accelerate research and development. This is likely to include product engineering, clinical validation, regulatory progress, and broader commercial readiness.
As the company scales, integration partnerships with surgical system manufacturers and healthcare providers could become an important route to adoption. Compatibility with robotic and minimally invasive systems may also position Hypervision Surgical within a fast-growing segment of hospital technology spending.
About Hypervision Surgical
Hypervision Surgical is a medtech company developing real-time hyperspectral imaging technology for surgery. Founded in 2021 as a spin-out from King’s College London and headquartered in London, the company combines advanced optics and AI analytics to help surgeons assess tissue more accurately during procedures.
